Oncology Central

It’s checkmate for Opdivo small-cell lung cancer trial

Bristol-Myers Squibb (NY, USA) have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer (SCLC). The Phase III CheckMate-331 study failed to show results above those of currently used therapies and did not meet the endpoints of the study.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.